Shares of DexCom, Inc. (NASDAQ:DXCM - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $84.86, but opened at $86.76. DexCom shares last traded at $85.41, with a volume of 126,946 shares.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the stock. Morgan Stanley raised their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Piper Sandler reduced their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Citigroup reissued a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Mizuho assumed coverage on shares of DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Finally, Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and raised their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.32.
Get Our Latest Report on DXCM
DexCom Price Performance
The firm has a market capitalization of $34.17 billion, a PE ratio of 60.94, a P/E/G ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a fifty day moving average price of $74.94 and a 200-day moving average price of $78.79.
DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 EPS. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.
Insider Activity
In other news, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at $26,183,401.02. This trade represents a 8.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president now owns 109,621 shares in the company, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 83,110 shares of company stock worth $6,103,505. Corporate insiders own 0.32% of the company's stock.
Institutional Investors Weigh In On DexCom
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC raised its stake in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Caprock Group LLC increased its holdings in DexCom by 86.0% in the 4th quarter. Caprock Group LLC now owns 6,515 shares of the medical device company's stock worth $507,000 after buying an additional 3,012 shares during the period. Heck Capital Advisors LLC purchased a new position in DexCom during the 4th quarter worth approximately $38,000. China Universal Asset Management Co. Ltd. lifted its stake in DexCom by 24.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,580 shares of the medical device company's stock valued at $512,000 after acquiring an additional 1,274 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of DexCom by 8.7% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 13,956 shares of the medical device company's stock valued at $1,085,000 after acquiring an additional 1,115 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.
About DexCom
(
Get Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
